I think it's very disruptive at this time.
Two new CMOs now have steep learning curves about RAC, Zantrene and epitranscriptomics just when trials are being designed. If the trials were already underway, it might be less disruptive.
And no sooner is the interim CMO up to speed than he will be gone.
Also, if David leaving has been known for a long time, why hasn't a new permanent CMO been found already? Maybe that's easier said than done. So it's disruptive.
Ann: Chief Medical Officer Appointment, page-79
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.010(0.64%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.64 | $1.55 | $134.0K | 84.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6283 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 6559 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |